Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976452 | 0.85 | CA1 (0.57) | ALDH1A1CYP3A4TDP1THRBALOX15 | |
| SCHEMBL10890265 | 0.85 | CA12 (0.48) | ALDH1A1TDP1CA12CA1CA2 | |
| SCHEMBL1530134 | 0.84 | CA12 (0.52) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7904243 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP3A4TDP1THRBALOX15 | |
| Lithium SCHEMBL31041157 | 0.82 | CYP17A1 (0.63) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL11233535 | 0.82 | PTGS1 (0.55) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL2034092 | 0.81 | LMNA (0.52) | ALDH1A1CYP3A4CA12CA1CA2 | |
| SCHEMBL5551069 | 0.79 | HPGD (0.54) | ALDH1A1CYP3A4THRBALOX15RECQL | |
| SCHEMBL10941982 | 0.79 | CA12 (0.52) | ALDH1A1CYP3A4ALOX15CA12CA1 | |
| SCHEMBL392853 | 0.78 | CA12 (0.55) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4477271-B1 | N-(PHENYL)-5-(HETEROARYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4477271-A2 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-12-18 | — | — | EP | disclosed |
| EP-3749648-B1 | N-(PHENYL)-5-(PHENYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2024-10-30 | — | — | EP | disclosed |
| US-20240277852-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4341254-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-111836801-B | Compounds for inhibiting TNIK and medical use thereof | 韩国化学硏究院 | 2024-02-02 | — | — | CN | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-02-09 | — | — | US | disclosed |
| WO-2010019910-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | ALDH1A1 261/4885CYP3A4 3060/4885TDP1 3239/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | ALDH1A1 428/4885CYP3A4 2749/4885TDP1 3293/4885 |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | ALDH1A1 4519/4885CYP3A4 4748/4885TDP1 1047/4885 |
| US-20240277852-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | PIP4K2A, PIP4K2C, PIP4K2B | ALDH1A1 4766/4885CYP3A4 3880/4885TDP1 1592/4885 |
| US-20230039679-A1 | COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | ALDH1A1 4519/4885CYP3A4 4748/4885TDP1 1047/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | ALDH1A1 1136/4885CYP3A4 528/4885TDP1 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.